Avalo Therapeutics Inc (AVTX) |
|
Price: $4.3700
$-0.63
-12.600%
|
Day's High:
| $5.07
| Week Perf:
| -22.24 %
|
Day's Low: |
$ 4.37 |
30 Day Perf: |
-13.64 % |
Volume (M): |
29 |
52 Wk High: |
$ 1,130.40 |
Volume (M$): |
$ 127 |
52 Wk Avg: |
$202.78 |
Open: |
$5.00 |
52 Wk Low: |
$3.95 |
|
|
Market Capitalization (Millions $) |
1 |
Shares
Outstanding (Millions) |
0 |
Employees |
- |
Revenues (TTM) (Millions $) |
2 |
Net Income (TTM) (Millions $) |
8 |
Cash Flow (TTM) (Millions $) |
-7 |
Capital Exp. (TTM) (Millions $) |
0 |
Avalo Therapeutics Inc
Avalo Therapeutics Inc is a pharmaceutical company that focuses on developing novel cancer therapies. The company's primary aim is to develop treatments that can harness the body's immune system to fight against cancer, particularly in patients whose tumors exhibit resistance to existing therapies. Avalo Therapeutics is dedicated to advancing innovative immunotherapy approaches and discovering new targets for effective cancer treatment.
Company Address: 540 Gaither Road, Suite 400 Rockville 20850 MD
Company Phone Number: 522-8707 Stock Exchange / Ticker: NASDAQ AVTX
AVTX is expected to report next financial results on March 28, 2024. |
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Management Announcement
Published Thu, Dec 7 2023 12:00 PM UTC
Introduction Avalo Therapeutics, Inc. (Nasdaq: AVTX) has recently called on its stockholders to actively participate in the adjourned annual meeting of stockholders. The meeting, initially held on December 5, 2023, lacked the required quorum to approve the crucial reverse stock split proposal. Avalo Therapeutics is strongly encouraging its stockholders to vote in fa...
|
Avalo Therapeutics Inc
During the past 5 trading days, Avalo Therapeutics Inc shares have experienced a significant decline of -10.14%. This brings the year-to-date performance to a staggering -98.2%. Additionally, Avalo Therapeutics Inc shares are currently trading 12.2% above its 52-week low. The reason behind this decline in share price can be attributed to the disastrous fiscal interval ending September 30, 2023, as reported by the major pharmaceutical preparations company. During this period, the company witnessed a drastic decline in revenue, specifically by -98.421%, amounting to only $0.24 million. This is a significant decrease compared to the similar reporting period a year ago. Furthermore, the net loss per share has extended to $-0.11 from the preceding reporting period's $-0.59 per share. Revenue also tumbled by -63.297% to $0.64 million.
|
Earnings announcement
Published Tue, Oct 31 2023 11:00 AM UTC
In a groundbreaking move, Avalo Therapeutics, Inc. has recently announced the completion of the divestiture of its rights, title, and interest in the AVTX-800 Series to AUG Therapeutics, LLC (AUG). The AVTX-800 Series includes AVTX-801 (D-galactose), AVTX-802 (D-mannose), and AVTX-803 (L-fucose), collectively known as the 800 Series. This successful divestiture represen...
|
Avalo Therapeutics Inc
Avalo Therapeutics Inc, a major pharmaceutical preparations company, has experienced a decline in its stock performance over the course of the last five trading days. The stock price went down by -25.25%, adding to a year-to-date performance of -96.22%. However, it is worth noting that despite this decline, the stock still trades 8.3% above its 52-week low. Looking at the company's financial performance for the fiscal time-frame ending June 30, 2023, Avalo Therapeutics Inc has shown some improvements. The company was able to decrease its loss per share from $-1.38 to $-0.59 compared to the previous year. Additionally, its income per share improved from $-0.85 in the previous quarter.
|
Avalo Therapeutics Inc
Avalo Therapeutics Inc has revealed its first quarter results for 2023, achieving a return on average invested assets (ROI) of 84.18%. This is a significant improvement compared to the fourth quarter of 2022, but still falls below the average ROI of -28.9% for AVTX. While the company's net income has deteriorated, investors can take solace in the improved ROI. However, within the Healthcare sector there are 230 other companies with a higher return on investment, and Avalo Therapeutics Inc's total ranking has deteriorated from 17 to 2876 compared to the previous quarter. Unfortunately, there is some cause for concern as the company's Q1 2023 report shows a disastrous fall in revenue of -59.506% to just $0.48 million. Moreover, the shortfall per share has widened to $-0.85, an increase from the comparable quarter in 2022 and the previous quarter. Overall, revenue tumbled by -46.987% from $0.90 million compared to the previous quarter. However, despite these figures, Avalo Therapeutics Inc did manage to narrow its net shortfall to $-9.955 million compared to $-22.051 million for the same period last year.
|
Per Share |
Current |
Earnings (TTM) |
-622.23 $ |
Revenues (TTM) |
11.36 $
|
Cash Flow (TTM) |
- |
Cash |
51.41 $
|
Book Value |
74.21 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-622.23 $
|
Revenues (TTM) |
11.36 $ |
Cash Flow (TTM) |
- |
Cash |
51.41 $
|
Book Value |
74.21 $ |
Dividend (TTM) |
0 $ |
|
|
|
|